Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Narrative (Details)

v3.23.3
Fair Value Measurements - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Jul. 31, 2023
USD ($)
item
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jul. 01, 2022
USD ($)
May 31, 2021
USD ($)
Apr. 06, 2021
USD ($)
Interest expense   $ 4,893 $ 3,790          
Income Tax Expense (Benefit), Total   (1,435) $ 13,982          
Exchange Traded Investment Grade Bond Funds                
Investments, Total       $ 25,000        
Investments, Fair Value Disclosure, Total       23,700        
Acquisition of Asuragen Inc and Namocell, Inc                
Contingent consideration   1,800            
Maximum contingent consideration   100,000            
Asuragen, Inc.                
Contingent consideration   1,000   2,000       $ 18,300
Maximum contingent consideration   105,000            
Namocell Inc                
Contingent consideration   800   $ 1,500   $ 10,600    
Maximum contingent consideration   25,000            
Forward starting swaps | Cash flow hedges | Designated as hedging instruments                
Derivative, Notional Amount         $ 100,000   $ 200,000  
Cross-currency swap | Net investment hedge | Designated as hedging instruments                
Derivative, Notional Amount $ 150,000              
Number of interim settlement dates | item 4              
Notional amount at maturity   $ 110,000            
Decrease in notional amount at each interim date $ 10,000